Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tau Interest Rising As Janssen Licenses AC Immune Alzheimer’s Vaccine

This article was originally published in The Pink Sheet Daily

Executive Summary

AC Immune of Switzerland will work with Janssen on a therapeutic Tau-targeted vaccine for Alzheimer’s that is in Phase Ib and which could be used in combination with beta-amyloid based approaches to maximize therapeutic responses to the disease. J&J also has licensed a pioneering microbiome drug from Vedanta.

You may also be interested in...



TauRx’s Data Massage Can't Work Out The Kinks Of Failed LMTX Study

While the company is hyping the benefit seen in a subgroup analysis of the first Phase III trial of the tau aggregation inhibitor, which failed to show an overall benefit in mild-to-moderate Alzheimer's disease, Datamonitor Healthcare analyst Maha Elsayed raises some questions.

Private Neurology Companies: Back In The Saddle Again

START-UP reviews five years of fundraising and exit activities for privately held biopharma companies developing neurology treatments. Next month we’ll delve into neurology medtech and diagnostics companies’ capital-raising and bow-outs.

A Busy Year-End, In Brief: December Brings Slate Of Approvals, And Setbacks

In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

OM006922

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel